Download PDF
Semin Thromb Hemost 2001; 27(6): 593-604
DOI: 10.1055/s-2001-18865
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Disseminated Intravascular Coagulation in Acute Leukemia

Tiziano Barbui, Anna Falanga
  • Hematology Department, Ospedali Riuniti, Bergamo, Italy
Further Information

Publication History

Publication Date:
06 December 2001 (online)

    Permissions and Reprints

ABSTRACT

Malignancy is associated with a ``hypercoagulable'' state and a high risk for thrombohemorrhagic complications. Clinical complications may range from localized thrombosis to bleeding of varying degrees of severity because of disseminated intravascular coagulation (DIC). Life-threatening bleeding is frequent in acute leukemias, particularly in acute promyelocytic leukemia (APL). Laboratory assessments show profound hemostatic imbalance in this condition, with activation of coagulation, fibrinolysis, and nonspecific proteolysis systems. An important pathogenetic role is attributed to the leukemic cell properties interfering with the hemostatic mechanisms. However, chemotherapy and intercurrent infections also contribute to the bleeding risk in the patient with leukemia. In this article, we will attempt to describe what is currently known about the coagulopathy of acute leukemia, summarize the various aspects of the hemostatic abnormalities underlying this disorder, and revise the principal pathogenetic mechanisms. We will also try to provide information on the current therapeutic tools and recommendations for the management of life-threatening bleeding in this disease. Finally, a special focus will be devoted to the management of this complication in the era of all-trans retinoic acid (ATRA), a drug now indispensable in curing APL that has completely changed the natural history of APL and its coagulation/bleeding syndrome.

KEYWORD

Malignancy - leukemia - hypercoagulability - DIC - ATRA

REFERENCES

  • 1 Rickles F R, Edwards R L. Activation of blood coagulation in cancer: Trousseau's syndrome revisited.  Blood . 1983;  62 14-31
    PubMedSearch in Google Scholar
  • 2 Falanga A, Rickles F R. Pathophysiology of the thrombophilic state in the cancer patient.  Semin Thromb Hemost . 1999;  25 173-182
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Tallman M S, Kwaan H C. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia.  Blood . 1992;  79 543-553
    PubMedSearch in Google Scholar
  • 4 Barbui T, Finazzi G, Falanga A. The management of bleeding and thrombosis in acute leukemia and chronic myeloproliferative disorders. In: Henderson ES, Lister TA, Greaves MF, eds. Leukemia, 7th ed. Chapter 16 Philadelphia: W.B. Saunders 2001
    Search in Google Scholar
  • 5 Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia.  Blood . 1998;  91 3093-3102
    PubMedSearch in Google Scholar
  • 6 Rickles F R, Levine M N, Edwards R L. Hemostatic alterations in cancer patients.  Cancer Met Rev . 1992;  11 237-248
    CrossrefPubMedSearch in Google Scholar
  • 7 Falanga A, Barbui T, Rickles F R, Levine M N. Guidelines for clotting studies in cancer patients.  Thromb Haemost . 1993;  70 343-350
    PubMedSearch in Google Scholar
  • 8 Falanga A, Ofosu F A, Delaini F. The hypercoagulable state in cancer: Evidence for impaired thrombin inhibition.  Blood Coagul Fibrinolysis . 1994;  5 S19-S23
    PubMedSearch in Google Scholar
  • 9 Poggi A, Donati M B, Garattini S. Fibrin and cancer cell growth: Problems in the evaluation of experimental models. In: Donati MB, Davison JF, Garattini S, eds. Malignancy and the Hemostatic System New York: Raven Press 1981: 89-101
    Search in Google Scholar
  • 10 Lyman G H, Bettigole R E, Robson E, Ambrus J L, Urban H. Fibrinogen kinetics in patients with neoplastic disease.  Cancer . 1978;  41 1113-1122
    PubMedSearch in Google Scholar
  • 11 Bani M R, Falanga A, Alessio M G. Blood coagulation changes in nude mice bearing human colon carcinomas.  Int J Cancer . 1992;  50 75-79
    PubMedSearch in Google Scholar
  • 12 Edwards R L, Rickles F R, Moritz T E. Abnormalities of blood coagulation tests in patients with cancer.  Am J Clin Pathol . 1987;  88 596-602
    PubMedSearch in Google Scholar
  • 13 Goad K E, Gralnick H R. Coagulation disorders in cancer.  Hematol Oncol Clin North Am . 1996;  10 457-484
    CrossrefPubMedSearch in Google Scholar
  • 14 Barbui T, Finazzi G, Falanga A, Battista R, Bassan R. Bleeding and thrombosis in acute lymphoblastic leukemia.  Leuk Lymphoma . 1993;  11(Suppl 2) 43-47
    PubMedSearch in Google Scholar
  • 15 Warrell R P, de The H, Wang Z Y, Degos L. Acute promyelocytic leukemia.  N Engl J Med . 1993;  329 177-189
    CrossrefPubMedSearch in Google Scholar
  • 16 Fenaux P. Management of acute promyelocytic leukemia.  Eur J Haematol . 1993;  50 65-73
    PubMedSearch in Google Scholar
  • 17 Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients.  Blood . 1990;  75 2112-2117
    PubMedSearch in Google Scholar
  • 18 Falanga A. Mechanisms for hypercoagulation in malignancy and during chemotherapy.  Haemostasis . 1998;  28(Suppl 3) 50-60
    CrossrefPubMedSearch in Google Scholar
  • 19 Bauer K A, Rosenberg R D. Thrombin generation in acute promyelocytic leukaemia.  Blood . 1984;  64 791-796
    CrossrefPubMedSearch in Google Scholar
  • 20 Booth N A, Bennett B. Plasmin-alpha-2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis.  Br J Haematol . 1984;  56 545-556
    CrossrefPubMedSearch in Google Scholar
  • 21 Reddy V B, Kowal-Vern A, Hoppensteadt D A. Global and hemostatic markers in acute myeloid leukemia.  Am J Clin Pathol . 1990;  94 397-403
    PubMedSearch in Google Scholar
  • 22 Speiser W, Pabinger-Fasching I, Kyrle P A. Hemostatic and fibrinolytic parameters in patients with acute myeloid leukemia: Activation of blood coagulation, fibrinolysis and unspecific proteolysis.  Blut . 1990;  61 298-302
    PubMedSearch in Google Scholar
  • 23 Dombret H, Scroboaci M L, Ghorra P. Coagulation disorders associated with acute promyelocytic leukemia: Corrective effect of all-trans-retinoic acid.  Leukemia . 1993;  7 2-9
    PubMedSearch in Google Scholar
  • 24 Kawai Y, Watanabe K, Kizaki M. Rapid improvement of coagulopathy by all-trans-retinoic acid in acute promyelocytic leukemia.  Am J Hematol . 1994;  46 184-188
    PubMedSearch in Google Scholar
  • 25 Falanga A, Iacoviello L, Evangelista V. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia given all-trans-retinoic acid.  Blood . 1995;  86 1072-1084
    PubMedSearch in Google Scholar
  • 26 Müller-Berghaus G, Niepoth M, Rabens Alles B, Rump E, Murano G. Normal antithrombin III activity and concentration in experimental disseminated intravascular coagulation.  Scand J Clin Lab Invest . 1985;  45 107-113
    PubMedSearch in Google Scholar
  • 27 Rodeghiero F, Mannucci P M, Viganò S. Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin in acute leukaemia.  Blood . 1984;  63 965-969
    PubMedSearch in Google Scholar
  • 28 Avvisati G, ten Cate W J, Lamping R. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukemia.  Br J Haematol . 1988;  70 43-48
    CrossrefPubMedSearch in Google Scholar
  • 29 Schwartz B S, Williams E C, Conlan M G, Mosher D F. Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia: acquired α-2-antiplasmin inhibitor deficiency.  Ann Intern Med . 1986;  105 873-878
    PubMedSearch in Google Scholar
  • 30 Menell J S, Cesarman G M, Jacovina A T. Annexin II and bleeding in acute promyelocytic leukemia.  N Engl J Med . 1999;  340 994-1004
    CrossrefPubMedSearch in Google Scholar
  • 31 Nemerson Y. The tissue factor pathway of blood coagulation.  Semin Hematol . 1992;  29 170-176
    PubMedSearch in Google Scholar
  • 32 Andoh K, Kubota T, Takada M. Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation.  Cancer . 1987;  59 748-754
    PubMedSearch in Google Scholar
  • 33 Falanga A, Gordon S G. Isolation and characterization of cancer procoagulant: A cysteine proteinase from malignant tissue.  Biochemistry . 1985;  24 5558-5567
    CrossrefPubMedSearch in Google Scholar
  • 34 Donati M B, Gambacorti Passerini C, Casali B. Cancer procoagulant in human tumor cells: Evidence from melanoma patients.  Cancer Res . 1986;  46 6471-6474
    PubMedSearch in Google Scholar
  • 35 Gordon S G, Hashiba U, Poole M A, Cross B A, Falanga A. A cysteine proteinase procoagulant from amnion-chorion.  Blood . 1985;  66 1261-1265
    PubMedSearch in Google Scholar
  • 36 Gouault-Heilman M, Chardon E, Sultan E, Josso F. The procoagulant factor of leukemic promyelocytes: Demonstration of immunologic cross-reactivity with human brain tissue factor.  Br J Haematol . 1975;  30 151-158
    PubMedSearch in Google Scholar
  • 37 Bauer K A, Conway E M, Bach R. Tissue factor gene expression in acute myeloblastic leukemia.  Thromb Res . 1989;  56 425-430
    CrossrefPubMedSearch in Google Scholar
  • 38 Falanga A, Alessio M G, Donati M B, Barbui T. A new procoagulant in acute leukemia.  Blood . 1988;  71 870-875
    PubMedSearch in Google Scholar
  • 39 Alessio M G, Falanga A, Consonni R. Cancer procoagulant in acute lymphoblastic leukemia.  Eur J Haematol . 1990;  45 78-81
    CrossrefPubMedSearch in Google Scholar
  • 40 Donati M B, Falanga A, Consonni R. Cancer procoagulant in acute non lymphoid leukemia: Relationship of enzyme detection to disease activity.  Thromb Haemost . 1990;  64 6-11
    PubMedSearch in Google Scholar
  • 41 Falanga A, Consonni R, Marchetti M. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by retinoic acid.  Leukemia . 1994;  8 156-159
    PubMedSearch in Google Scholar
  • 42 Koyama T, Hirosawa S, Kawamata N, Tohda S, Aoki N. All-trans-retinoic acid upregulates thrombomodulin and downregulates tissue factor expression in acute promyelocytic leukemia cells: Distinct expression of thrombomodulin and tissue factor in human leukemic cells.  Blood . 1994;  84 3001-3009
    PubMedSearch in Google Scholar
  • 43 De Stefano V, Teofili L, Sica S. Effect of all-trans-retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia.  Blood . 1995;  86 3535-3541
    PubMedSearch in Google Scholar
  • 44 Falanga A, Consonni R, Marchetti M. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid (ATRA) in acute promyelocytic leukemia cells.  Blood . 1998;  92 143-151
    PubMedSearch in Google Scholar
  • 45 Gordon S G. Tumor cell procoagulants and their role in malignant disease.  Semin Thromb Hemost . 1992;  18 424-433
    PubMedSearch in Google Scholar
  • 46 Falanga A, Marchetti M, Giovanelli S, Barbui T. All-trans-retinoic acid counteracts endothelial cell procoagulant activity induced by a human promyelocytic leukemia-derived cell line (NB4).  Blood . 1996;  87 613-617
    PubMedSearch in Google Scholar
  • 47 Conese M, Montemurro P, Fumarulo R. Inhibitory effects of retinoids on the generation of procoagulant activity by blood mononuclear phagocytes.  Thromb Haemost . 1991;  66 662-665
    PubMedSearch in Google Scholar
  • 48 Gralnick H R, Abrell E. Studies on the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukemia.  Br J Haematol . 1973;  24 89-99
    CrossrefPubMedSearch in Google Scholar
  • 49 Bennett B, Booth A, Croll A, Dawson A A. The bleeding disorder in acute promyelocytic leukemia: Fibrinolysis due to u-PA rather than defibrination.  Br J Haematol . 1989;  71 511-517
    CrossrefPubMedSearch in Google Scholar
  • 50 Francis R B, Seyfert U. Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation. Clinicopathologic correlations.  J Lab Clin Med . 1987;  110 541-547
    PubMedSearch in Google Scholar
  • 51 Stephens R, Alitalo R, Tapiovaara H, Vaheri A. Production of an active urokinase by leukemia cells. A novel distinction from cell lines of solid tumors.  Leuk Res . 1988;  12 419-422
    CrossrefPubMedSearch in Google Scholar
  • 52 Egbring R, Schmidt W, Fuchs G, Havemann K. Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects.  Blood . 1977;  49 219-231
    CrossrefPubMedSearch in Google Scholar
  • 53 Schmidt W, Egbring R, Havemann K. Effect of elastase-like and chymotrypsin-like neutral proteases from human granulocytes on isolated clotting factors.  Thromb Res . 1975;  6 315-329
    CrossrefPubMedSearch in Google Scholar
  • 54 Brower M S, Harpel P C. Proteolytic cleavage and inactivation of α-2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase.  J Biol Chem . 1982;  257 9849-9854
    PubMedSearch in Google Scholar
  • 55 Sterrenberg L, van Liempt J G, Nieuwenhuizen W, Hermans J. Anticoagulant properties of purified X-like fragments of human fibrinogen produced by degradation with leukocyte elastase.  Thromb Haemost . 1984;  51 398-402
    PubMedSearch in Google Scholar
  • 56 Sterrenberg L, Nieuwenhuizen W, Hermans J. Purification and characterization of a D-like fragment from human fibrinogen produced by human leukocyte elastase.  Biochim Biophys Acta . 1983;  775 300-306
    PubMedSearch in Google Scholar
  • 57 Wijermans P W, Rebel V I, Ossenkoppele G J, Huijgens P C, Langenhuijsen M A C M. Combined procoagulant activity and proteolytic activity of acute promyelocytic leukemic cells: Reversal of the bleeding disorder by cell differentiation.  Blood . 1989;  73 800-805
    PubMedSearch in Google Scholar
  • 58 Tapiovaara H, Matikainen S, Hurme M, Vaheri A. Induction of differentiating therapy of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors.  Blood . 1994;  83 1883-1891
    CrossrefPubMedSearch in Google Scholar
  • 59 Griffin J D, Rambaldi A, Vellenga E. Secretion of interleukin-1 by acute myeloid leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors.  Blood . 1987;  70 1218-1221
    PubMedSearch in Google Scholar
  • 60 Cozzolino F, Torcia M, Miliani A. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia.  Am J Med . 1988;  84 240-250
    CrossrefPubMedSearch in Google Scholar
  • 61 Colucci M, Balconi G, Lorenzet R. Cultured human endothelial cells generate tissue factor in response to endotoxin.  J Clin Invest . 1983;  71 1893-1896
    PubMedSearch in Google Scholar
  • 62 Bevilacqua M P, Pober J S, Majeau G R. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin-1.  Proc Natl Acad Sci USA . 1986;  83 4533-4537
    CrossrefPubMedSearch in Google Scholar
  • 63 Dittman W A, Majerus P W. Structure and function of thrombomodulin: A natural anticoagulant.  Blood . 1990;  75 329-336
    PubMedSearch in Google Scholar
  • 64 Moore K L, Esmon C T, Esmon N L. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture.  Blood . 1989;  73 159-165
    PubMedSearch in Google Scholar
  • 65 Nachman R L, Hajar K A, Silverstein R L, Dinarello C A. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor.  J Exp Med . 1993;  163 1595-1600
    PubMedSearch in Google Scholar
  • 66 Suffredini A F, Harpell P C, Parrillo J E. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects.  N Engl J Med . 1989;  320 1165-1172
    CrossrefPubMedSearch in Google Scholar
  • 67 van Hinsberg W M V, Bauer K A, Kooistra T. Progress of fibrinolysis during tumor necrosis factor infusion in humans. Concomitant increase of tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.  Blood . 1990;  76 2284-2289
    PubMedSearch in Google Scholar
  • 68 Dubois C, Schlageter M H, de Gentile A. Modulation of IL-8, IL-1β, and G-CSF by all-trans retinoic acid in acute promyelocytic leukemia.  Leukemia . 1994;  8 1750-1757
    PubMedSearch in Google Scholar
  • 69 Giannì M, Norio P, Terao M. The effect of dexamethasone on proinflammatory cytokine expression, cell growth and maturation during granulocytic differentiation of acute promyelocytic leukemia cells.  Eur Cytokine Network . 1995;  6 157-165
    PubMedSearch in Google Scholar
  • 70 Ishii H, Horie S, Kizaki K, Kazama M. Retinoic acid counteracts both the downregulation of thrombomodulin and the induction of tissue factor in cultured human endothelial cells exposed to tumor necrosis factor.  Blood . 1992;  80 2556-2562
    PubMedSearch in Google Scholar
  • 71 Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function.  FASEB J . 1992;  6 2591-2599
    PubMedSearch in Google Scholar
  • 72 Giavazzi R, Foppolo M, Dossi R, Remuzzi A. Rolling and adhesion of human tumor cells on vascular endothelium under physiological flow conditions.  J Clin Invest . 1993;  92 3038-3044
    CrossrefPubMedSearch in Google Scholar
  • 73 Rickles F R, Edwards R L. Leukocytes and tumor cells in thrombosis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice Philadelphia: Lippincott 1994: 1164-1179
    Search in Google Scholar
  • 74 Marchetti M, Falanga A, Giovanelli S, Oldani E, Barbui T. All-trans-retinoic acid increases the adhesion to endothelium of the acute promyelocytic leukemia cell line NB4.  Br J Haematol . 1996;  93 360-366
    CrossrefPubMedSearch in Google Scholar
  • 75 Marchetti M, Vignoli A, Barbui T, Falanga A. Endothelial cell/leukemic cell interaction: Effects of all-trans retinoic acid on cell/cell adhesion.  Thromb Haemost . 1999;  82(Suppl) 16 Abst
    PubMedSearch in Google Scholar
  • 76 Lee A Y, Levine M N. The thrombophilic state induced by therapeutic agents in the cancer patient.  Semin Thromb Hemost . 1999;  25 137-145
    Thieme ConnectPubMedSearch in Google Scholar
  • 77 Bertomeu M C, Gallo S, Lauri D. Chemotherapy enhances endothelial cell reactivity to platelets.  Clin Exp Metastasis . 1990;  8 511-518
    CrossrefPubMedSearch in Google Scholar
  • 78 Nicolson G L, Custead S E. Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity.  Cancer Res . 1985;  45 331-336
    PubMedSearch in Google Scholar
  • 79 Sporn L A, Rubin P, Marder V J, Wagner D D. Irradiation induces release of von Willebrand protein from endothelial cells in culture.  Blood . 1984;  64 567-570
    PubMedSearch in Google Scholar
  • 80 Poggi A, Kornblitt L, Delaini F. Delayed hypercoagulability after a single dose of adriamycin to normal rats.  Thromb Res . 1979;  16 639-650
    CrossrefPubMedSearch in Google Scholar
  • 81 Bazarbachi A, Scrobohachi M L, Gisselbrecht C. Changes in protein C, factor VII and endothelial markers after autologous bone marrow transplantation: Possible implications in the pathogenesis of veno-occlusive disease.  Nouv Rev Fr Haematol . 1993;  35 135-140
    PubMedSearch in Google Scholar
  • 82 Catani L, Gugliotta L, Vianelli N. Endothelium and bone marrow transplantation.  Bone Marrow Transplant . 1996;  17 277-280
    PubMedSearch in Google Scholar
  • 83 Aoki N, Harpel P C. Inhibitors of the fibrinolytic enzyme system.  Semin Thromb Hemost . 1984;  10 24-41
    PubMedSearch in Google Scholar
  • 84 Harper P L, Jarvis J, Jennings I, Luddington R, Marcus R E. Changes in the natural anticoagulants following bone marrow transplantation.  Bone Marrow Transplant . 1990;  5 39-42
    PubMedSearch in Google Scholar
  • 85 Haskell C M, Canellos G P, Leventhal B G. L-asparaginase. Therapeutic and toxic effects in patients with neoplastic disease.  N Engl J Med . 1969;  281 1028-1034
    PubMedSearch in Google Scholar
  • 86 Homans A C, Rybak M E, Baglini R L. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia.  J Clin Oncol . 1987;  5 811-817
    PubMedSearch in Google Scholar
  • 87 Leone G, Gugliotta L, Mazzucconi M G. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: A GIMEMA study.  Thromb Haemost . 1993;  69 12-15
    PubMedSearch in Google Scholar
  • 88 Sarris A H, Kempin S, Berman E. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia.  Blood . 1992;  79 1305-1310
    PubMedSearch in Google Scholar
  • 89 Anderlini P, Luna M, Kantarjian H M. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.  Leukemia . 1996;  10 600-608
    PubMedSearch in Google Scholar
  • 90 Bishop J F, Lowenthal R M, Joshua D. Etoposide in acute nonlymphocytic leukemia.  Blood . 1990;  75 27-32
    PubMedSearch in Google Scholar
  • 91 Clawson C C, Rao G HR, White J G. Platelet interaction with bacteria. IV Stimulation of the release reaction.  Am J Pathol . 1975;  81 411-420
    PubMedSearch in Google Scholar
  • 92 MacIntyre D E, Allen A P, Thorne K JI. Endotoxin-induced platelet aggregation and secretion I. Morphological changes and pharmacological effects.  J Cell Sci . 1977;  28 211-23
    PubMedSearch in Google Scholar
  • 93 Semeraro N, Colucci M. Changes in the coagulation-fibrinolysis balance of endothelial cells and mononuclear phagocytes: Role in disseminated intravascular coagulation associated with infectious diseases.  Int J Clin Lab Res . 1992;  21 214-220
    CrossrefPubMedSearch in Google Scholar
  • 94 Shands Jr W J. The endotoxin-induced procoagulant of mouse exudate macrophages: A factor X activator.  Blood . 1983;  62 333-340
    PubMedSearch in Google Scholar
  • 95 Chang H Y, Rodriguez V, Narboni G. Causes of death in adults with acute leukemia.  Medicine . 1976;  55 259-268
    PubMedSearch in Google Scholar
  • 96 Murphy S, Litwin S, Herring L M. Indications for platelet transfusion in children with acute leukemia.  Am J Hematol . 1982;  12 347-356
    PubMedSearch in Google Scholar
  • 97 Kantarjian H M, Keating M J, Walters R S. Acute promyelocytic leukemia.  M.D. Anderson Hospital experience. Am J Med . 1986;  80 789-797
    CrossrefPubMedSearch in Google Scholar
  • 98 Goldberg M A, Ginsburg D, Mayer R J. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia?.  Blood . 1987;  69 187-191
    PubMedSearch in Google Scholar
  • 99 Bassan R, Battista R, Viero P. Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia.  Leukemia . 1995;  9 238-243
    PubMedSearch in Google Scholar
  • 100 Hashimoto S, Koike T, Tatewaki W. Fatal thromboembolism in acute promyelocytic leukemia during all-trans-retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage.  Leukemia . 1994;  8 1113-1115
    PubMedSearch in Google Scholar
  • 101 Castaigne S, Chomienne, Daniel M T. All-trans retinoic acid as a differentation therapy for acute promyelocytic leukemia.  Blood . 1990;  76 1704-1709
    PubMedSearch in Google Scholar
  • 102 Tallman M S, Andersen J W, Schiffer C A. A prospective randomized study of all-trans-retinoic acid induction and maintenance therapy for patients with acute promyelocytic leukemia.  N Engl J Med . 1997;  337 1021-1028
    CrossrefPubMedSearch in Google Scholar
  • 103 Burnett A K, Grimwade D, Solomon E. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans-retinoic acid: Results of the randomized MRC trial.  Blood . 1999;  93 4131-4143
    PubMedSearch in Google Scholar
  • 104 Fenaux P, Chastang C, Chevret S. A randomized comparison of all trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia.  Blood . 1999;  94 1192-1200
    PubMedSearch in Google Scholar
  • 105 Sanz M A, Martin G, Rayon C. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARa-positive acute promyelocytic leukemia.  Blood . 1999;  94 3015-3021
    PubMedSearch in Google Scholar
  • 106 Federici A B, Falanga A, Lattuada A. Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukemia by treatment with all-trans-retinoic acid.  Br J Haematol . 1996;  92 733-739
    CrossrefPubMedSearch in Google Scholar
  • 107 Horie S, Kisaki K, Ishii H, Kazama M. Retinoic acid stimulates expression of thrombomodulin, a cell surface anticoagulant glycoprotein, on human endothelial cells: Differences between up-regulation of thrombomodulin by retinoic acid and cAMP.  Biochem J . 1992;  281 149-154
    PubMedSearch in Google Scholar
  • 108 Kooistra T, Opdenberg J P, Toet K. Stimulation of tissue-type plasminogen activators synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo.  Thromb Haemost . 1991;  65 565-572
    PubMedSearch in Google Scholar
  • 109 Semeraro N, Montemurro P, Conese M. Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynecological malignancies.  Int J Cancer . 1990;  45 251-254
    CrossrefPubMedSearch in Google Scholar